Posted on September 18, 2012 by Sitemaster
According to a new article, to be published on line today in The Lancet, abiraterone acetate + prednisone provides a median overall survival benefit of 4.6 months compared to a placebo in men with metastatic, castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: abiraterone survival, castrate-resistant, mCRPC, metastatic | 15 Comments »
Posted on February 23, 2012 by Sitemaster
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a comment »
Posted on June 20, 2011 by Sitemaster
An article in the June issue of the journal Acta Oncologia discusses the potential of newer types of imaging technology as methods to monitor the progression of disease in men with castrate-resistant prostate cancer (CRPC). … READ MORE –
Filed under: Living with Prostate Cancer, Management | Tagged: castrate-resistant, imaging | Leave a comment »
